TABLE 2.
Cox proportional hazards regression analysis of omega-3 supplementation use and its blood biomarkers for AD risk in ADNI cohort
| AD cases/total | Model 1 |
P |
Model 2 |
P |
Model 3 |
P |
|
|---|---|---|---|---|---|---|---|
| HR (95%CI) | HR (95%CI) | HR (95%CI) | |||||
| Omega-3 supplementation | |||||||
| non-exposure | 248/863 | 1 (reference) | 1 (reference) | 1 (reference) | |||
| exposure | 59/272 | 0.73 (0.55-0.97) | 0.029 | 0.71 (0.53-0.94) | 0.018 | 0.72 (0.54-0.97) | 0.031 |
| medium-term exposure | 51/204 | 0.87 (0.64-1.18) | 0.370 | 0.84 (0.62-1.14) | 0.262 | 0.85 (0.62-1.16) | 0.304 |
| long-term exposure | 8/68 | 0.36 (0.18-0.72) | 0.004 | 0.35 (0.17-0.71) | 0.004 | 0.37 (0.18-0.75) | 0.006 |
| Blood markers | |||||||
| omega-3 | 287/867 | 0.91 (0.52-1.61) | 0.752 | 1.15 (0.65-2.03) | 0.640 | 1.28 (0.71-2.30) | 0.407 |
| DHA | 287/867 | 0.86 (0.57-1.30) | 0.485 | 1.05 (0.70-1.57) | 0.832 | 1.13 (0.74-1.71) | 0.571 |
| ALA | 287/867 | 1.08 (0.64-1.83) | 0.781 | 1.23 (0.74-2.05) | 0.428 | 1.27 (0.75-2.17) | 0.374 |
Model 1: crude HR with no covariates adjusted;
Model 2: HR adjusted for age, sex, education, clinical diagnosis, and APOE ε4;
Model 3: HR adjusted for Model 2 plus insomnia, depression, anxiety, hypertension, diabetes mellitus, hyperlipidemia, smoking, BMI, stroke, and coronary artery disease, alcohol intake, multivitamins, vitamin B12, folate, anti-hypertensive drugs and antidiabetic drugs.